About MaxCyte
MaxCyte is a company based in Gaithersburg (United States) founded in 1998. MaxCyte has raised $20.69 million across 14 funding rounds from investors including HHS, Harbert Management and Casdin Capital. The company has 114 employees. MaxCyte has completed 1 acquisition, including SeQure Dx. MaxCyte offers products and services including Electroporation Systems, Processing Assemblies, and Reagents. MaxCyte operates in a competitive market with competitors including SQZBiotech, Gemini Bio, Fluxion Biosciences, Berkeley Lights and LBT Innovations, among others.
- Headquarter Gaithersburg, United States
- Employees 114
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website maxcyte.com
- Social LinkedIn X
- Legal Name Maxcyte, Inc.
- Annual Revenue$33.03 M (USD)-14.5as on Dec 31, 2025
- Net Profit-$44.63 M (USD)-8.71as on Dec 31, 2025
- EBITDA-$38.4 M (USD)17.84as on Dec 31, 2025
- Total Equity Funding$20.69M (USD)
in 14 rounds
- Latest Funding Round$31.42M (USD), Post-IPO
May 2020
- InvestorsHHS
& 6 more
- Employee Count114
- Investments & Acquisitions
Products & Services of MaxCyte
MaxCyte offers a comprehensive portfolio of products and services, including Electroporation Systems, Processing Assemblies, and Reagents.
Devices for efficient cell transfection in therapy and research
Components for scalable electroporation workflows
Buffers and accessories for cell engineering processes
Funding Insights of MaxCyte
MaxCyte has successfully raised a total of $20.69M across 14 strategic funding rounds. The most recent funding activity was a Post-IPO round of $31.42 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20.69M
- Total Rounds 14
- Last Round Post-IPO — $31.42M
- First Round $10.7M
(Mar 2004)
- Investors Count 7
Latest 10 of 14 funding rounds of MaxCyte with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2020 | $31.42M | Post-IPO | – | – | |
| Feb 2019 | $13.06M | Post-IPO | – | – | – |
| Sep 2016 | $760,308 | Post-IPO | – | – | – |
| Jun 2015 | $500,000 | Grant | – | – | |
| Dec 2014 | $1.7M | Series B | – | – | – |
| Aug 2009 | $1.5M | Series B | – | – | – |
| Aug 2009 | – | Debt – Conventional | – | – | – |
| Mar 2009 | $809,064 | Grant | – | – | |
| Jun 2008 | $2.13M | Series B | – | – | – |
| Mar 2008 | $809,064 | Grant | – | – |
7 investors in total: 7 institutional.
Investors in MaxCyte
MaxCyte has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Harbert Management and Casdin Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investing in Life Sciences sectors like Healthcare and Biotechnology. | – | casdincapital.com | - | |
Sofinnova Partners is focused on life sciences and healthcare investments. | – | sofinnovapartners.com | Paris, France | |
Stem cell research startups in healthcare are funded and accelerated. | – | mscrf.org | Columbia, United States | |
Early-stage life sciences and tech focused VC firm funding companies in the US | – | intersouth.com | Durham, United States | |
Seed and early stage tech and life sciences focused VC firm funding companies in the US and Europe | – | talloakscapital.com | Charlottesville, United States | |
Infrastructure, hedge, private equity, and debt fund focused on multiple sectors | 1993 | harbert.net | Birmingham, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for MaxCyte
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MaxCyte
20 people are tracked at MaxCyte (8 in leadership, 8 in board & advisors, 4 in team); the tracked headcount is 114.
| Name | Role | Group |
|---|---|---|
Maher Masoud | Executive Vice President and General Counsel | Leadership |
Crystal Kirk | Director Of Accounting | Leadership |
Jack Horgan | Vice President Of Corporate Development | Leadership |
Jay Gelfman | VP, Finance | Leadership |
Jessica McClure | VP, Sales, Americas | Leadership |
Douglas Swirsky | CFO | Leadership |
Ana-Paula Martins-Fernandes | Senior Vice President & Head, Global Sales | Leadership |
Sandeep Pandit | Director, Manufacturing Engineering | Leadership |
Art Mandell | Non-Executive Director | Board & advisors |
John Johnston | Non-Executive Director | Board & advisors |
Will Brooke | Non-Executive Director | Board & advisors |
Stan Erck | Non-Executive Director | Board & advisors |
Yasir Al-Wakeel | Non-Executive Director | Board & advisors |
Rekha Hemrajani | Non-Executive Director | Board & advisors |
Patrick J. Balthrop, Sr. | Non-Executive Director | Board & advisors |
Richard Douglas | Non-Executive Chairman | Board & advisors |
Marie-Laure Joandel | Sales Manager | Team |
Angel Galarza | Business Development Manager | Team |
Sarah Schuett | Business Development Manager | Team |
Anna Otal Navarro | Sales Manager – Spain, Portugal, And Italy | Team |
Complete people profiles for MaxCyte
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of MaxCyte
MaxCyte is a publicly listed company on the NASDAQ with ticker symbol MXCT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Jul 2021
- Listed onNASDAQ: MXCT
- Listed entityMaxCyte, Inc.
- Exchange sectorHealth technology
- ISINUS57777K1060
- Share price$1.01 (-0.98% on the day) · 2026-10-09
- Market capitalisation$104.2M
- EPS (diluted, trailing year)$-0.33
- Volume (last session)240,006
Financials of MaxCyte
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $33.0M | -$44.6M | -$38.4M |
| 2024 | $38.6M | -$41.0M | -$46.7M |
| 2023 | $41.3M | -$37.9M | -$44.0M |
| 2022 | $44.3M | -$23.6M | -$24.6M |
| 2021 | $33.9M | -$19.1M | -$16.7M |
Detailed financial statements for MaxCyte
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MaxCyte
MaxCyte has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SeQure Dx.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of personalized diagnostics for gene-editing therapies | sequre-dx.com | Waltham, United States | 2020 | Jan 2025 | •••• |
Complete acquisition details for MaxCyte
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of MaxCyte
5 dated milestones of MaxCyte across 27 years, from founding to its latest funding, stage changes and deals.
- Founded MaxCyte is founded.
- Funding First funding round of $10.7M.
- Funding Latest funding round, Post-IPO, of $31.4M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires SeQure Dx.
Competitors of MaxCyte
MaxCyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SQZBiotech, Gemini Bio, Fluxion Biosciences, Berkeley Lights and LBT Innovations, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sqzbiotech.com | 2013 | Boston, United States | $167.41M | 117 | Cell therapies are developed using proprietary Cell Squeeze technology. | |
| geminibio.com | 1985 | West Sacramento, United States | $5.68M | 79 | Supplement reagents for cell and gene therapy are manufactured. | |
| fluxionbio.com | 2005 | San Francisco, United States | $20.85M | – | Microfluidics-based tools for cellular analysis are provided. | |
| berkeleylights.com | 2011 | Emeryville, United States | $124.72M | 267 | Microfluidics-based systems for single-cell isolation and analysis are developed. | |
| lbtinnovations.com | 2004 | Adelaide, Australia | – | – | Developer of AI-based automated solutions for the preparation and analysis of microbiology culture specimens | |
| mytos.bio | 2016 | London, United Kingdom | $19M | 19 | Developer of automated cell culture instruments | |
| stamm.bio | 2017 | San Francisco, United States | $17.25M | – | Cell processing platforms are developed for research and industries. | |
| thrivebio.com | 2014 | Boston, United States | $15.13M | – | Developer of smart devices for life science cell culture | |
| unicornb.io | 2020 | Cambridge, United Kingdom | $3.2M | 5 | Bioreactors and automated systems for cell-based manufacturing are developed. |
Detailed competitors of MaxCyte
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MaxCyte
The website of MaxCyte (maxcyte.com) receives about 11.2K visits a month and ranks #1,958,980 among all websites worldwide, #2,665 in Biotechnology and Pharmaceuticals.
- Monthly visits11.2K
▼ 11.7% vs previous month
- Unique visitors5.9K
per month
- Global rank#1,958,980
among all websites
- Category rank#2,665
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.6
- Average visit25 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with MaxCyte. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| immunomix.com | 100% | 2.7K | #5,105,289 | View details | |
| americangene.com | 100% | 16.6K | #1,411,276 | View details | |
| senseibio.com | 99% | 4.5K | #4,696,262 | View details | |
lonzabio.jp | lonzabio.jp | 83% | – | #1,579,919 | – |
| iovance.com | 82% | 16.2K | #1,264,131 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for MaxCyte
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Maxcyte
Complete news archive for MaxCyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to MaxCyte
10 companies that operate in the same segment as MaxCyte (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about MaxCyte
MaxCyte was founded in 1998 and raised its 1st funding round 6 years after it was founded.
MaxCyte is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
MaxCyte is a funded company, having raised a total of $20.69M across 14 funding rounds to date. The company's 1st funding round was a Grant of $809.06K, raised on Mar 2004.
MaxCyte has 114 employees.
Annual revenue of MaxCyte is $33.03M as on Dec 31, 2025.
MaxCyte was founded in 1998 and is headquartered in Gaithersburg, United States. Operations focus on the biotechnology sector, where instrument systems for cell processing and modification are developed and supplied. Key products include the MaxCyte STX, a flow electroporation-based system for single transfections, and the MaxCyte VLX for large-volume transient transfections. Additional services encompass transfection insourcing, such as producing cells with targets of interest and recombinant proteins.
MaxCyte's top competitors include SQZBiotech, Mytos and Thrive Bioscience.
MaxCyte offers Electroporation Systems, Processing Assemblies, and Reagents.
Yes, MaxCyte is publicly traded on NASDAQ under the ticker symbol MXCT.
MaxCyte has made 1 acquisition, including SeQure Dx.
MaxCyte has 7 investors. Key investors include HHS, Harbert Management, Casdin Capital, Sofinnova Partners, and Maryland Stem Cell Research Fund.
MaxCyte operates through Maxcyte, Inc..